RecruitingNCT06369480

Prognostic Factors for Survival in Patients With Cholangiocarcinoma


Sponsor

Rigshospitalet, Denmark

Enrollment

2,000 participants

Start Date

Feb 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The objective of this retrospective study is to determine the survival rates of CCA patients based on different therapeutic approaches. Additionally, we aim to investigate the risk factors associated with poor survival within a cohort of patients treated over a seven-year period across four Danish hospitals. We anticipate that our findings could provide additional evidence for clinical decision-making, improve patient outcomes, and contribute to the knowledge in the field.


Eligibility

Inclusion Criteria1

  • Patients' eligibility for this study is contingent on a diagnosis of CCA confirmed by the MDT from Aalborg Universitetshospital, Aarhus Universitetshospital, Odense Universitetshospital, and Rigshospitalet in Denmark from 2013 to 2020.

Exclusion Criteria1

  • We will exclude from the analysis all records with more than one interventions. Additionally, all patients whose cholangiocarcinoma diagnosis was canceled following the MDT meeting will be also excluded, as well those with inconsistent data regarding date of reference to the MDT.

Interventions

PROCEDUREResection/Ablation of tumor

Curative treatment

PROCEDUREPalliative chemotherapy

Chemotherapeutic medications

PROCEDURENeoadjuvant chemotherapy

Chemotherapeutic medications after surgery

PROCEDUREStereotatic radiotherapy

Radiotherapy

PROCEDUREBest supportive care

Symptomatic treatment, non-curative treatment


Locations(1)

Rigshospitalet

Copenhagen, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06369480


Related Trials